Skip to contentB
BridgeBio Pharma, Inc.
B
BBIOBridgeBio Pharma, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$154.18M$154.18Mderived+2,521.2% vs Q4 2024 Net Income-$186.63M-$186.63MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BridgeBio Pharma, Inc. · CIK 1743881 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$139,562,000N/M Operating Cash Flowderived-$56,420,000N/M Free Cash Flowderived-$56,453,000N/M Margins · derivedOperating margin-90.5%+3752.2 pt vs Q4 2024
Net margin-121.0%+4295.9 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 24, 2026 · 55 d after period end